NRAS and melanoma: Immunogenicity is inferred by the fact that homologous NRAS mutations (ILDTAGKEEY, ILDTAGREEY) have been shown to be immunogenic in HLA-A*01:01-positive melanoma patients and presentation of the peptides was shown by immunopeptidomics (53).